CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to enhance immunotherapy for Acute Myeloid Leukemia by identifying regulators of natural killer cell ligands that leukemia stem cells suppress. By understanding how these ligands are activated or inhibited, the research seeks to improve treatment options for patients with AML.
Acute Myeloid Leukemia (AML) is the most common adult leukemia, with a high frequency of relapse and mortality.
After therapy, the persistence of rare leukemia stem cells (LSCs) with disease initiating and therefore stem cell-like properties is a likely cause for relapse.
Therefore, novel therapeutic strategies to specifically eradicate LSCs are urgently needed.
Natural Killer-cells (NK-cells) are innate immune cells capable of detecting cell surface ligands to trigger a cytotoxic response again…
DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
